Publication: Methotrexate plus narrow band ultraviolet B (NBUVB) versus methotrexate alone in the treatment of moderate to severe plaque psoriasis: A randomized clinical trial
| dc.contributor.author | Khadka, Dhan Keshar | |
| dc.contributor.author | Agrawal, S | |
| dc.contributor.author | Dhali, T K | |
| dc.date.accessioned | 2025-08-16T08:01:32Z | |
| dc.date.available | 2025-08-16T08:01:32Z | |
| dc.date.issued | 2015 | |
| dc.description | Dhan Keshar Khadka Department of Dermatology and Venereology, B. P. Koirala Institute of Health Sciences, Dharan S Agrawal Department of Dermatology and Venereology, B. P. Koirala Institute of Health Sciences, Dharan T K Dhali Department of Dermatology and Venereology, ESIC PGIMSR, New Delhi | |
| dc.description.abstract | Abstract: Introduction: Psoriasis is a chronic, recurring inflammatory disease affecting the skin, joints and nails that has a significant negative impact on the quality of life. Efficacy of combination of methotrexate/narrowband ultraviolet B (NBUVB) phototherapy in the treatment of psoriasis has been rarely assessed. Objectives: To compare the therapeutic efficacy of methotrexate plus NBUVB phototherapy combination vs. methotrexate in the treatment of moderate to severe chronic plaque psoriasis. Material and methods: Seventy-nine patients with chronic plaque-type psoriasis (body surface area involvement >2%) were randomized to receive either methotrexate/NBUVB phototherapy (group A) or methotrexate (group B). End point of treatment was 75% reduction in Psoriasis Area and Severity Index (PASI75) Score or up to 12weeks, whichever was earlier. Patients were then followed up for a period of 12 weeks for assessment of adverse effect, DLQI and relapse. Results: Of 79 patients, 69 completed the treatment period and follow-up. PASI 75 was achieved in 35/39(89%) patients in group A and 34/40(85%) patients in group B (P=0.052). The mean number of weeks (P = 0.031), the mean cumulative dose of NBUVB (8.2±3.5J/cm2)) and the mean number of phototherapy sessions (12±3)) required to achieve PASI 75 were less in group A compared with group B. There was no significant difference in the number of patients who relapsed during the follow- up period (P = 0.68). Conclusion: Combination of methotrexate and NBUVB phototherapy provides more rapid clinical improvement compared with methotrexate monotherapy in the treatment for chronic plaque-type psoriasis. Keywords: DLQI, Methotrexate, NBUVB, PASI, Psoriasis | |
| dc.identifier | https://doi.org/10.3126/njdvl.v13i1.14298 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/1629 | |
| dc.language.iso | en_US | |
| dc.publisher | Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON) | |
| dc.title | Methotrexate plus narrow band ultraviolet B (NBUVB) versus methotrexate alone in the treatment of moderate to severe plaque psoriasis: A randomized clinical trial | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.article.type | Original Article | |
| oaire.citation.endPage | 23 | |
| oaire.citation.startPage | 12 |